ImmunityBio, Inc. ((IBRX), a commercial-stage immunotherapy company, today announced two poster presentations and one online publication at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 2, 2026, in Chicago.

The presentations span two randomized Phase 3 trials in advanced NSCLC and a matched adjusted indirect comparison (MAIC) in BCG unresponsive non-muscle invasive bladder cancer (NMIBC), and collectively evaluate ANKTIVA® (nogapendekin alfa inbakicept-pmln), the company's IL-15 receptor agonist immunotherapy designed to activate natural killer (NK) cells, CD4+ and CD8+ T cells, and memory T cells, across multiple solid tumor indications.